Option Care Health delivered a strong second quarter, reporting 15.4% revenue growth to $1.416 billion, with both its acute and chronic care portfolios showing mid-teen gains. “The acute therapy growth we delivered in the quarter was notably higher than we believe the overall market to be growing,” said CFO Mike Shapiro on a recent call to discuss the company’s earnings. “(In the) acute portfolio, the product margins are north of 50%. The chronic portfolio presents anywhere from 5% to 30% margin profiles.” Option Care navigated pricing shifts and biosimilar competition, including a $20 million headwind from Stelara—one of the first 10 drugs subject to negotiation under the Inflation Reduction Act. That’s up from $5 million in Q1.
Read the full article: Option Care Fueled by Balanced Portfolio, Strong Margins, Strategic Expansion //
Source: https://www.hmenews.com/article/option-care-fueled-by-balanced-portfolio-strong-margins-strategic-expansion